tbuckley/cabot-search huggingface dataset:
Identification of markers RREB1, MYB, CCND1 and centromere 6 for the discrimination between melanoma and nevi FFPE skin biopsies using fish
Authors: Susan Jewell, Beth Blondin, Mona Legator, Kris Jacobson, John Schulz, Teresa Ruffalo, Paul Matushek, Larry Morrison, Boris Bastian
Journal: Cancer Research (2007)

135  Background: Melanoma is the deadliest type of skin cancer with rapidly increasing incidence rates world-wide. It can be cured by simple excision if recognized early. Once metastasis has occurred, successful treatment options are limited. The gold standard for the diagnosis is histopathology. Although, the majority of cases can be diagnosed unequivocally as melanoma or benign melanocytic nevus, there is a subset of cases that cannot be classified without ambiguity. Misdiagnosis can result in inappropriate over or under treatment of patients. Since early diagnosis and treatment of melanoma is crucial to prevent progression, efforts to identify tumor markers that can help detect melanoma in early stages of development are highly important.  To identify markers for the discrimination between melanoma and benign melanocytic nevi skin biopsies we used fluorescence in situ hybridization (FISH) to correlate the copy number status of several genomic regions found in prior studies to be frequently aberrant in melanomas but not in nevi.  Methods: We analyzed formalin-fixed, paraffin-embedded biopsies from 94 melanomas and 95 benign nevi that were histopathologically unequivocally malignant or benign, respectively using sets of FISH probe targeting the following genomic loci: 1q31 (COX2), 4q13 (KIT), 6p25(RREB1), 6q23 (MYB), centromere6, 7q34 (BRAF), centromere 7, 9p21 (CDKN2A), centromere 10, 11q13 (CCND1), 17q21 (RARA), 17q25 (NTRK1), centromere 17, and 20q13 (ZNF217). Average probe signals of 30 non-overlapping nuclei were obtained to determine copy number increases (>2 signals), copy number decreases ( 2 or   The five genomic regions with the best discriminatory ability were assembled into two panels: 6p25(RREB1)/6q23(MYB)/CEP® 6/11q13(CCND1) and 6p25(RREB1)/6q23(MYB)/ CEP® 6/ CEP® 10. These two probe sets were hybridized to 56 of the specimens and identified a probe combination with RREB1, MYB, CCND1 and CEP® 6 that had a sensitivity and specificity of 92 and 94%, respectively, to discriminate melanomas from nevi.  Conclusions: Our study identifiedcopy number changes of RREB1, MYB, centromere 6 and CCND1 as powerful discriminators between melanoma and nevi. A four-color FISH assay containing probes targeting RREB1, MYB, CEP® 6, and CCND1 may improve diagnostic accuracy of melanoma.
Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis
Authors: Micah Silaba, Michael Ooko, Christian Bottomley, Joyce Sande, Rachel Benamore, Kate Park, James Ignas, Kathryn Maitland, Neema Mturi, Anne Makumi, Mark Otiende, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Tahreni Bwanaali, Evasius Bauni, Fergus Gleeson, Maria Deloria Knoll, Ifedayo Adetifa, Kevin Marsh, Thomas N Williams, Tatu Kamau, Shahnaaz Sharif, Orin S Levine, Laura L Hammitt, J Anthony G Scott
Journal: The Lancet Global Health (2019)

Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is dominated by pneumonia, most of which is non-bacteraemic. We examined the effect of 10-valent PCV on the incidence of pneumonia in Kenya.
More talk than action: gender and ethnic diversity in leading public health universities
Authors: Mishal Sameer Khan, Fatim Lakha, Melisa Mei Jin Tan, Shweta Rajkumar Singh, Rina Yu Chin Quek, Emeline Han, See Mieng Tan, Victoria Haldane, Montserrat Gea-Sánchez, Helena Legido-Quigley
Journal: The Lancet (2019)
Genetic Risk of Severe Chronic Graft-Versus-Host Disease Defined By Host-Derived CXCR3 Ligands
Authors: Hao Dai, Sivaramakrishna P. Rachakonda, Olaf Penack, Aleksandar Radujkovic, Carsten Müller-Tidow, Olga Blau, Igor-Wolfgang Blau, Rajiv Kumar, Peter Dreger, Thomas Luft
Journal: Blood (2018)
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Authors: Hideaki Ogiwara, Kazuaki Takahashi, Mariko Sasaki, Takafumi Kuroda, Hiroshi Yoshida, Reiko Watanabe, Ami Maruyama, Hideki Makinoshima, Fumiko Chiwaki, Hiroki Sasaki, Tomoyasu Kato, Aikou Okamoto, Takashi Kohno
Journal: Cancer Cell (2019)
Abstract MP51: Lifetime Risk For Cardiovascular Disease Stratified By Fasting Glucose Level
Authors: Michael P Bancks, Hongyan Ning, Norrina B Allen, Mercedes R Carnethon, Justin Echouffo Tcheugui, Donald M Lloyd-Jones, John T Wilkins
Journal: Circulation (2018)

Introduction: Diabetes and insulin resistance are major contributors to atherosclerotic cardiovascular disease (ASCVD) risk, but the lifetime risks (LTR) associated with normoglycemia, impaired fasting glucose (IFG), and diabetes (DM) in middle-aged adults have not been reported. Hypothesis: Higher fasting glucose (FG) category will be associated with a monotonic increase in the LTR for ASCVD. Methods: We pooled data from 7 observational cohorts of US black and white men and women followed from 1960 through 2015. Categories of FG were normoglycemia (&lt;100 mg/dl), IFG (100-125 mg/dl), and DM (≥126 mg/dl or use of DM medications). ASCVD was defined as fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. Individuals were free of symptomatic ASCVD at index age 55 years. LTR for incident ASCVD after age 55 was estimated according to FG category using a modified Kaplan-Meier survival analysis, adjusted for the competing risk of non-ASCVD death. Results: Our sample included 19630 individuals (6197 blacks, 11015 women) without a prior ASCVD event. Mean baseline FG level was 90.1 mg/dl for normoglycemics, 107.4 mg/dl for IFG, and 176.6 mg/dl for DM. Greater age, body mass index, blood pressure, and male sex and black race were associated with increasing FG category. LTR for ASCVD through age 85 among women was 15.5% for normoglycemics, 16.4% for IFG, and 38.6% for DM (Figure 1A). Among men, LTR for ASCVD through age 85 was 22.2% for normoglycemia, 25.0% for IFG, and 47.7% for DM (Figure 1B). The difference in LTR for ASCVD between normoglycemics and IFG was not statistically significant for women (LTR difference 95% confidence interval (CI): -3.8, 2.0) or men (LTR difference 95% CI: -5.8, 0.2). Conclusion: LTRs for ASCVD were similar among normoglycemia and IFG categories. However, LTR among middle-aged participants with DM were 39-48%; approximately twice as high as those with IFG. These data strongly support the importance of public health and clinical strategies that target prevention of incident DM by midlife.
Abstract 16726: Association of Renin-angiotensin System Inhibitors With Reduced Adverse Cardiac Events in Patients With Ischemic Mitral Regurgitation After Acute Myocardial Infarction
Authors: Kitae Kim, Shuichiro Kaji, Takafumi Yamane, Takeshi Kitai, Atsushi Kobori, Natsuhiko Ehara, Makoto Kinoshita, Yutaka Furukawa
Journal: Circulation (2015)

Background: Ischemic mitral regurgitation (IMR) portends a poor prognosis during long-term follow-up and has been identified as an independent predictor of heart failure (HF) and reduced long-term survival. Renin-angiotensin system inhibitors (RASI) including angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB) may improve prognosis in patients with IMR after acute myocardial infarction (AMI). The purpose of this study was to investigate the association of RASI with the incidence of adverse cardiac events in patients with IMR after AMI. Methods: We screened 867 consecutive patients admitted for AMI and underwent emergency coronary angiography between January 2000 and December 2008. A total of 388 patients who were diagnosed to have mild or greater MR evaluated by transthoracic echocardiography within 2 weeks after the onset were enrolled. Results: The mean age was 67±11 years and 297 patients (77%) were men. A total of 297 patients (77%) received RASI before hospital discharge. Patients without RASI were older and more likely to have higher creatinine level compared with patients with RASI. Left ventricular ejection fraction, peak CPK level, prevalence of prior MI were comparable between the two groups. The mean follow-up period was 5.4±3.4 years. During the follow-up, 22 cardiac deaths and 39 HF events occurred. Kaplan-Meier analysis revealed that freedom from cardiac death and HF was significantly higher in patients with RASI than in those without RASI (p&lt;0.001 and p=0.001, respectively). After adjustment with the inverse probability treatment weighting, Cox regression analysis showed a significant beneficial effect of RASI therapy in reducing cardiac death (hazard ratio [HR]: 0.20; p&lt;0.001) and HF (HR: 0.41; p=0.008). Conclusions: RASI was associated with a lower incidence of adverse cardiac events in patients with IMR after AMI.
High-titer IgG4 to cow’s milk proteins and relationship to specific IgE in Pediatric Eosinophilic Esophagitis
Authors: Lisa Workman, Jeffrey M. Wilson, Alexander J. Schuyler, Emily C. McGowan, Jonas Lidholm, Elizabeth A. Erwin, Thomas A.E. Platts-Mills
Journal: Journal of Allergy and Clinical Immunology (2019)
“Self-sacrifice” as an accidental outcome of extreme within-group mutualism
Authors: Antoine Marie
Journal: Behavioral and Brain Sciences (2018)

Abstract Whitehouse makes no room for evolutionary approaches to extreme behaviors based on partner choice and mutualism, which have been convincingly invoked to make sense of ordinary morality. Extended to intergroup warfare, these evolutionary mechanisms may play a pivotal role in explaining the existence of extreme – though not functionally sacrificial – behaviors, benefiting non-kin fellow fighters, together with the distinctive phenomenology those behaviors display.
Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma
Authors: Priya Sriskandarajah, Kevin Boyd, Wen Xu, Irene Moreno Candilejo, Sidra Ellis, Amy Price, Amy L Sherborne, James Croft, Vallari Shah, Joanna Dawes, Mona Parmar, Alison Turner, Emma Hall, Nina Tunariu, Juanita S Lopez, Johann S. de Bono, Udai Banerji, Martin Kaiser
Journal: Blood (2018)
Evaluation of routine image follow-up in nonmetastatic colorectal cancer after curative surgical resection.
Authors: Lara Azevedo Diniz, Amanda Karani, Diogo De Brito Sales, Larissa Machado, Milton Jose Barros
Journal: Journal of Clinical Oncology (2019)

524 Background: Follow-up surveillance is performed after primary treatment in colorectal cancer (CRC), but it is controversial in the literature the real benefit of an intensive examination in terms of outcomes and resources. Intensive follow-up after surgery for colorectal cancer has been challenged by some new published data (CEA watch trial and FACS trial). These new data suggest that a less intensive follow-up program based on carcinoembryonic antigen (CEA) measurements or CEA-Triggered imaging would be enough to detected most of the recurrences. We believe that there is a high percentage of patients with recurrence disease and normal CEA value, for whom image screening would be necessary to detect early disease recurrence suitable to metastasectomy with curative intention. Methods: This is a retrospective study that included 372 patients from a tertiary cancer center in São-Paulo (Brazil) diagnosed with colorectal adenocarcinoma stages I to III. We observed, after primary treatment, a pattern of recurrence detected either by CT (computed tomography) imaging only or CEA elevation and CT image in combination. Results: Out of the 372 patients analyzed, 110 (29,5%) had recurrent disease with a median follow-up time of 34 months. Of the 110 recurrences detected, 75 (68,18%) were detected by CEA elevation in combination with CT image, 33 (30%) were detected only by CT image and 2 (1,81%) neither by CT nor by CEA alteration. There was no clinic feature that would predict pattern of recurrence when analyzed by qui square test. Metastasectomy rate from this analysis 53,6% and it was similar among both groups. Recurrence rate after metastasectomy was 59,3%. There is a 5-year overall survival difference between patients that underwent or not metastasectomy (79,4% vs. 54%, p 0,01). Conclusions: CEA-based follow-up program and CEA-triggered imaging failed to detect early recurrence in almost 30% of cases. We believe that this number is high enough to allow us to continue to perform image test during CRC follow-up.
PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes
Authors: Shuji Akizuki, Kazuyoshi Ishigaki, Yuta Kochi, Sze-Ming Law, Keitaro Matsuo, Koichiro Ohmura, Akari Suzuki, Manabu Nakayama, Yusuke Iizuka, Haruhiko Koseki, Osamu Ohara, Jun Hirata, Yoichiro Kamatani, Fumihiko Matsuda, Takayuki Sumida, Kazuhiko Yamamoto, Yukinori Okada, Tsuneyo Mimori, Chikashi Terao
Journal: Annals of the Rheumatic Diseases (2019)

Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterised by autoantibody production and widespread inflammation damaging many organs. Previous genome-wide association studies (GWASs) have revealed over 80 genetic determinants of SLE, but they collectively explain a fraction of the heritability, and only a few were proven in vivo for the involvement in SLE. We conducted a meta-analysis of SLE GWAS in the Japanese population, followed by functional analyses of a susceptibility gene with use of mutant mice.We conducted a meta-analysis of two GWASs comprising a total of 1363 cases and 5536 controls using the 1000 Genome Project data as an imputation reference. Enrichment analyses for functional annotations were conducted. We examined Phospholipase D4 (Pld4) mutant mice to assess functional involvement of a genetic determinant.We found a total of 14 significant loci, which included rs2582511 in AHNAK2/PLD4 recently reported in a Chinese study and a novel locus of rs143181706 in MAMLD1 (p=7.9×10-11 and 3.7×10-8, respectively). PLD4 risk allele was associated with anti-dsDNA antibody production. Enrichment analysis of genetic signals revealed involvement of a wide range of immune-related cells and pathways. Pld4 mutant mice revealed remarkably low body weight. The mice demonstrated autoimmune phenotypes compatible with SLE, including splenomegaly and lymphadenopathy, expansion of B cells and hypersecretion of BAFF and production of autoantibodies especially anti-nuclear antibody and anti-dsDNA antibody.We found a novel susceptibility gene to SLE. Pld4 mutant mice revealed autoimmune phenotypes suggesting functional involvement of PLD4 with the basics of SLE.
The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE® Mediated T-Cell Response
Authors: Anetta Marcinek, Bettina Brauchle, Dragica Udiljak, Roman Kischel, Peter Kufer, Karsten Spiekermann, Michael von Bergwelt, Felix S. Lichtenegger, Marion Subklewe
Journal: Blood (2018)
Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors
Authors: Audrey Mansuet-Lupo, Marc Barritault, Marco Alifano, Aurélie Janet-Vendroux, Makmoud Zarmaev, Jérôme Biton, Yoan Velut, Christine Le Hay, Isabelle Cremer, Jean-François Régnard, Ludovic Fournel, Bastien Rance, Marie Wislez, Pierre Laurent-Puig, Ronald Herbst, Diane Damotte, Hélène Blons
Journal: Journal of Thoracic Oncology (2019)
Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients
Authors: Valeria Grancini, Maddalena Trombetta, Maria Elena Lunati, Maria Linda Boselli, Stefano Gatti, Maria Francesca Donato, Eva Palmieri, Veronica Resi, Giuseppe Pugliese, Riccardo C. Bonadonna, Emanuela Orsi
Journal: Journal of Hepatology (2019)
Abstract 20603: The Impact of a Real-Time Physiologic Data Analytic Index on Length of Stay in Neonates Following Surgery for Congenital Heart Disease
Authors: Joshua W Salvin, Dimitar Baranov, Peter C Laussen
Journal: Circulation (2017)

Introduction: Predictive indices of hemodynamics may be modelled from the acquisition of continuous physiologic data, but to date are not related to a specific outcome. The Inadequate Oxygen Delive...
Abstract 17695: Deletion of Rictor in Smooth Muscle Cells Negligibly Affects the Development of Pulmonary Hypertension
Authors: Kang Wu, Haiyang Tang, Yali Gu, Angela Balistrieri, Jian Wang, Ayako Makino, Jason X Yuan
Journal: Circulation (2017)

Rationale: Pulmonary arterial hypertension (PAH) is a progressive and fatal disease in which elevated pulmonary arterial pressure (PAP) is caused by increased pulmonary vascular resistance (PVR). P...
The effect of muscarinic M3 receptor blockage in development of M2 macrophages in allergic inflammation
Authors: Shin Ohta, Megumi Jinno, Akihiko Tanaka, Tomoki Uno, Yoshitaka Uchida, Ryo Manabe, Hitomi Ida, Naota Kuwahara, Yosuke Fukuda, Tomoyuki Kimura, Kukniaki Hirai, Yoshito Miyata, Munehiro Yamaguchi, Tetsuya Homma, Fumihiro Yamaguchi, Yoshio Watanabe, Shintaro Suzuki, Tsukasa Ohnishi, Hironori Sagara, Sojiro Kusumoto
Journal: Journal of Allergy and Clinical Immunology (2019)
A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
Authors: Uwe Pelzer, Johanna C. Bendell, Mark S. Womack, Nathan Bahary, Teresa Macarulla, Erkut Hasan Borazanci, Donna Elise Levy, Gary Mo, Samuel Cowan Ramage, Ignacio Garrido-Laguna
Journal: Journal of Clinical Oncology (2019)

330 Background: Increased platelet-derived growth factor receptor alpha (PDGFRα) expression is linked to epithelial-mesenchymal transition in pancreatic cancer. Olaratumab (O) is a fully human monoclonal antibody against PDGFRα previously approved for the treatment of advanced soft tissue sarcoma. Here, we report the initial safety and antitumor activity data of O in combination with nab-paclitaxel + gemcitabine (nPG) in first-line metastatic pancreatic cancer patients (pts). Methods: In this 3+3 dose escalation study, pts with stage IV pancreatic cancer received intravenous 15 mg/kg (cohort 1) or 20 mg/kg (cohort 2) O + nPG (125 mg/m 2 /1000 mg/m 2 ) on D1, 8, and 15 of a 28-day cycle. Following dose escalation, additional pts were enrolled in an expansion phase to confirm safety. Primary objective was to determine a dose of O that can be safely combined with nPG. Results: As of September 2018, 10 pts were treated in dose escalation (cohort 1: 3 pts; cohort 2: 7 pts) with no dose-limiting toxicities (DLTs) observed. Safety of 20 mg/kg O + nPG was confirmed in the expansion cohort; 1 of 12 pts (8.3%) experienced a DLT of grade 4 neutropenia. Most frequent adverse events (AEs) (≥ 25%) reported across all cohorts included fatigue (50%); neutropenia (50%); nausea (46%); thrombocytopenia (41%); and constipation (32%). Related grade ≥ 3 AEs reported in &gt; 2 pts were neutropenia (N = 7; 32%), infusion-related reaction, and neuropathy (both N = 3; 14%). There were no deaths related to study drugs. Among pts evaluable for response, 2 of 15 pts had a partial response and 11 pts had stable disease as best response for an objective response rate of 13%. Notably, 2 of 3 pts in cohort 1 continue on treatment for more than 12 months as of the data cut-off. Updated data will be presented at the meeting. Conclusions: Both dose levels were tolerated. Safety profile was similar to nPG chemotherapy with most toxicity manageable through dose adjustments of nPG. Clinical trial information: NCT03086369.
Dysfunctional CLEC-2 and GPVI-Mediated Signaling in Syk Y342F Knock-in Mouse Platelets
Authors: John C Kostyak, Benjamin R Mauri, Carol A Dangelmaier, Akruti Patel, Monica Wright, Haritha G Reddy, Johannes A Eble, Satya P. Kunapuli
Journal: Blood (2018)
Abstract 20725: Antidepressant Use by Class and Major Adverse Cardiac Events in Coronary Artery Disease Patients
Authors: Jose Medina-Inojosa, Sherry Grace, Randal Thomas, Heather Krause, Kristin Vickers Douglas, Brian Palmer, Francisco Lopez-Jimenez
Journal: Circulation (2017)

Introduction: Cognitive-behavioral therapy and antidepressant drugs (ADD) are recommended when depression is detected in coronary artery disease (CAD) patients. While some classes are shown to be s...
Development of antirhinoviral DNAzymes for effective prevention of asthma exacerbations
Authors: Daniel P. Potaczek, Sebastian D. Unger, Nan Zhang, Styliani Taka, Sven Michel, Nesibe Akdag, Feng Lan, Markus Helfer, Christoph Hudemann, Markus Eickmann, Chrysanthi Skevaki, Spyridon Megremis, Anne Sadewasser, Bilal Alashkar Alhamwe, Fahd Alhamdan, Mubeccel Akdis, Michael Edwards, Sebastian L. Johnston, Cezmi A. Akdis, Stephan Becker, Claus Bachert, Nikolaos G. Papadopoulos, Holger Garn, Harald E. Renz
Journal: Journal of Allergy and Clinical Immunology (2019)
HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Alpha Beta and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies
Authors: Liang Piu Koh, Wing H. Leung, Michelle Poon, Lip Kun Tan, Poh Lin Tan, Balamurugan Vellayappan, Rajat Bhattacharyya, Ah Moy Tan, Teck Guan Soh, Yeh Ching Linn
Journal: Blood (2018)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Authors: Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D. Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F. Stephen Hodi, Myung-Ju Ahn, Leisha A. Emens, Fabrice Barlesi, Omid Hamid, Emiliano Calvo, David McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Tsuhako, Kari Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis
Journal: Clinical Cancer Research (2019)

IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer.The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecutive days of each cycle with the exception of cycle 1, where navoximod administration started on day -1 to characterize pharmacokinetics. Atezolizumab was administered by intravenous infusion 1,200 mg every 3 weeks on day 1 of each cycle.Patients (n = 157) received navoximod at 6 dose levels (50-1,000 mg) in combination with atezolizumab. The maximum administered dose was 1,000 mg twice daily; the MTD was not reached. Navoximod demonstrated a linear pharmacokinetic profile, and plasma Kyn generally decreased with increasing doses of navoximod. The most common treatment-related AEs were fatigue (22%), rash (22%), and chromaturia (20%). Activity was observed at all dose levels in various tumor types (melanoma, pancreatic, prostate, ovarian, head and neck squamous cell carcinoma, cervical, neural sheath, non-small cell lung cancer, triple-negative breast cancer, renal cell carcinoma, urothelial bladder cancer): 6 (9%) dose-escalation patients achieved partial response, and 10 (11%) expansion patients achieved partial response or complete response.The combination of navoximod and atezolizumab demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer. Although activity was observed, there was no clear evidence of benefit from adding navoximod to atezolizumab.